BLA 022458 · Pfizer
Elelyso
Taliglucerase Alfa · Intravenous · Hydrolytic Lysosomal Glucocerebroside-specific Enzyme
NovelOrphanLast checked: Nov 20, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
May 1, 2012
Approved uses
4
Original approval plus efficacy supplements
Registered trials
11
6 Phase 3, 0 recruiting
FAERS reports
576
418 serious, 49 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS Patients treated with enzyme replacement therapies have experienced life‑threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Initiate ELELYSO in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue ELELYSO and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life‑threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur [see Warnings and Precautions (5.1) ] . WARNING: HYPERSENSITIVITY REACTIONS INCLUDING...
What it is approved for
From the label in effect Dec 29, 2025.
ELELYSO is indicated for the treatment of patients 4 years of age and older with a confirmed diagnosis of Type 1 Gaucher disease. ELELYSO is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for the treatment of patients 4 years and older with a confirmed diagnosis of Type 1 Gaucher disease ( 1 ).
Mechanism: Gaucher disease is an autosomal recessive disorder caused by mutations in the human glucocerebrosidase gene, which results in a reduced activity of the lysosomal enzyme glucocerebrosidase. Glucocerebrosidase catalyzes the conversion of the sphingolipid glucocerebroside into glucose and ceramide. The enzymatic deficiency results in accumulation of substrate glucocerebroside primarily in the lysosomal compartment of macrophages, giving rise to foam cells or "Gaucher cells," which accumulate in the liver, spleen and bone marrow. ELELYSO, an enzyme replacement therapy, is a recombinant analog of...
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 20, 2016 Supplement 13 · Efficacy OrphanLetterLabel
- Nov 20, 2015 Supplement 7 · Efficacy LabelLetter
- Aug 27, 2014 Supplement 3 · Efficacy OrphanLetterLabel
- May 1, 2012 Original approval · Type 1 - New Molecular Entity NovelOrphanReviewLetterLabel
1 products under this application
- ELELYSO · TALIGLUCERASE ALFA 200 UNITS/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Taliglucerase Alfa" as an intervention, any sponsor and status, largest first.
- Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension TrialPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00705939 · 45 participants · Start Jun 2008 · Primary completion May 2012
Drug: Taliglucerase alfa · For: Gaucher Disease
Sites: Decatur, Georgia; New York, New York; Parkville, Australia · 11 sites in all
- A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher DiseasePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00376168 · 32 participants · Start Aug 2007 · Primary completion Sep 2009
Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD); Plant cell expressed recombinant glucocerebrosidase (prGCD) · For: Gaucher Disease
Sites: Coral Springs, Florida; Decatur, Georgia; New York, New York · 11 sites in all
- Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human GlucocerebrosidasePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00712348 · 31 participants · Start Dec 2008 · Primary completion Apr 2013
Drug: Taliglucerase alfa · For: Gaucher Disease
Sites: Coral Springs, Florida; Decatur, Georgia; New York, New York · 10 sites in all
Shaare Zedek Medical CenterAcademic, hospital or other
NCT04353466 · 30 participants · Start Jan 1, 2017 · Primary completion Jul 31, 2021
Drug: Elelyso · For: Gaucher Disease, Type 1
- A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher DiseasePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01422187 · 19 participants · Start Aug 2011 · Primary completion May 2014
Drug: Taliglucerase alfa · For: Gaucher Disease
- A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher DiseasePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01411228 · 15 participants · Start Sep 2011 · Primary completion Jul 2014
Drug: Taliglucerase alfa · For: Gaucher Disease
Sites: Jerusalem, Israel; Barrio Asunción, Paraguay; Morningside, South Africa
Ari ZimranAcademic, hospital or other
NCT04002830 · 14 participants · Start Nov 20, 2020 · Primary completion Jul 30, 2023
Drug: Elelyso · For: Gaucher Disease, Type 3
Sites: New Delhi, India; Jerusalem, Israel; Ankara, Turkey (Türkiye)
PfizerPfizer (PFE)
NCT01132690 · 11 participants · Start Aug 2010 · Primary completion May 2012
Drug: Taliglucerase alfa · For: Gaucher Disease
Sites: Jerusalem, Israel; Barrio Sajonia Asunción, Paraguay; Morningside, South Africa
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue71
- arthralgia47
- headache47
- off label use47
- malaise46
- pain46
- pyrexia46
- pain in extremity45
- dyspnoea40
- inappropriate schedule of product administration38
- nausea38
- back pain36
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2011 | 2 |
| 2012 | 12 |
| 2013 | 37 |
| 2014 | 25 |
| 2015 | 29 |
| 2016 | 46 |
| 2017 | 60 |
| 2018 | 57 |
| 2019 | 38 |
| 2020 | 49 |
| 2021 | 24 |
| 2022 | 40 |
| 2023 | 30 |
| 2024 | 39 |
| 2025 | 55 |
| 2026 | 32 |
Recalls
2 FDA enforcement reports for this application.
Feb 27, 2020 · Class II · Terminated
Lack of Assurance of Sterility--Reports of loose metal ferrule crimps on vials for injection. The entire cap either lifted or dislodged while attempting to flip off the orange color plastic button.
Sep 19, 2018 · Class II · Terminated
Lack of assurance of sterility -Reports of loose metal ferrule crimps on vials for injection. The entire cap either lifted or dislodged while attempting to flip off the orange color plastic button.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Elelyso (Taliglucerase Alfa)
2024 spending
$2.8M
Beneficiaries
n/a
62 claims
Per beneficiary
n/a
$873.09 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,027,301 |
| 2021 | $3,135,062 |
| 2022 | $3,677,950 |
| 2023 | $2,779,778 |
| 2024 | $2,786,025 |
Part B: Elelyso (Taliglucerase Alfa) · HCPCS J3060
2024 spending
$5.0M
Beneficiaries
12
185 claims
Per beneficiary
$419,589
2024 ASP limit $44.30 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,825,582 |
| 2021 | $4,479,298 |
| 2022 | $4,550,835 |
| 2023 | $5,093,939 |
| 2024 | $5,035,065 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy.
Kuter DJ, Wajnrajch M, Hernandez B, et al. · Blood Cells Mol Dis 2020 · Clinical Trial, Phase III, Multicenter Study
- Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems-The taliglucerase alfa story.
Rup B, Alon S, Amit-Cohen BC, et al. · PLoS One 2017 · Clinical Trial, Phase III, Multicenter Study
- Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naïve patients with Gaucher disease.
Zimran A, Durán G, Mehta A, et al. · Am J Hematol 2016 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase.
Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, et al. · Blood Cells Mol Dis 2018 · Clinical Trial, Multicenter Study
- Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease.
Abbas R, Park G, Damle B, et al. · PLoS One 2015 · Multicenter Study, Randomized Controlled Trial
- Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.
Pastores GM, Shankar SP, Petakov M, et al. · Am J Hematol 2016 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.